LAURA RUMMEL: Open Payments
NPI 1497806921 · FULLERTON, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,164 in 50 payments from 15 companies in 2025. Trend: 2023 $1,263 · 2024 $1,388 · 2025 $1,164
Food & beverage: $1,164
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 8 | $189 |
| ABBVIE INC. | 12 | $160 |
| Regeneron Healthcare Solutions, Inc. | 4 | $155 |
| Incyte Corporation | 5 | $137 |
| UCB, Inc. | 4 | $104 |
| GENZYME CORPORATION | 2 | $98 |
| Lilly USA, LLC | 2 | $51 |
| Novartis Pharmaceuticals Corporation | 2 | $51 |
| Galderma Laboratories, L.P. | 3 | $50 |
| Arcutis Biotherapeutics, Inc. | 2 | $46 |
Products named: DUPIXENT, TREMFYA, OPZELURA, Bimzelx, BOTOX, TALTZ, COSENTYX, SKYRIZI.
Industry payments across CA — which companies pay providers there.
